Overview

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

Status:
Unknown status

Trial end date:
2019-08-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

Conatus Pharmaceuticals Inc.

Treatments:

Caspase Inhibitors